NASDAQ Congratulates Portfolio Insider: Among The Fastest Growing Fintechs In The U.S.
19.8.2021 13:00:00 EEST | Business Wire | Press release
NASDAQ congratulated Portfolio Insider on the iconic MarketSite tower’s LED electronic video display in Times Square as among the fastest-growing Fintech companies in America. The hyper growing financial analytics company has democratized access to valuable financial data, delivering nearly anyone the same level of investing insights enjoyed by institutions and hedge funds.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210819005136/en/
On Thursday, August 11, 2021, NASDAQ's Times Square New York City LED screen displayed a congratulatory message to artificial intelligence-powered financial insights platform Portfolio Insider. (Photo: Business Wire)
Record Growth This Year.
The pandemic spurred a flood of new retail investors into the stock market, making up nearly 34% of U.S. stocks according to the Federal Reserve. It created an unprecedented level of demand for financial insights. Portfolio Insider grew revenue by over 300% in only the first half of this year, hiring over 70 new staff to build out Blockchain Analytics and machine learning models for financial data. Senior analyst Christopher Koo said, “Accurate data underpins sound decision-making, and we see virtually no limit to the amount of demand for more powerful algorithms and tools to level the playing field.”
AI Technology To “Make Investing Human.”
Computer programmers used to strenuously translate their intentions into the language of machines. Now, leveraging the world's largest autoregressive language model, those machines are conversant with the language of humans. Portfolio Insider believes they can “make investing more human” by developing on one of the most powerful neural networks ever created. By applying artificial intelligence to areas like unstructured data in financial reports, heuristic search, and a human intuitive SQL-like query for fundamental financial data, it enables anyone to build their own Bloomberg terminal for free. Portfolio Insider Chief AI Officer Noah Mitsuhashi said, “Technology has reached the evolutionary speed where intense tasks just years or months ago are now trivial and basic. Technology is growing exponentially, shaping a future where technology becomes virtually indistinguishable from magic. We contribute to human progress by enabling a fair playing field for retail investors.”
About The Company.
Portfolio Insider is a fintech analytics company powering the open finance revolution. They contribute to the Fintech landscape by democratizing access to the world's most valuable financial data and bring transparency to capital markets. Reaching millions of people each month, they provide on-chain market intelligence and real-time data services for institutional and retail stakeholders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210819005136/en/
Contact information
Noah Mitsuhashi
323-483-4014
content@portfolioinsider.com
PortfolioInsider.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom